Farxiga

Farxiga (dapagliflozin) is an SGLT2 inhibitor that promotes glucose excretion and modest weight loss. Its mechanism is renal rather than mitochondrial thermogenesis. Equator’s drug candidate targets a distinct calorie-burning pathway that may provide additive benefits in metabolic syndrome patients already on SGLT2 therapy.